Menarini Silicon Biosystems has published data from a Phase III STIC CTC study that supported the reliability of using circulating tumour cell (CTC) count to guide frontline therapy choice for patients with estrogen receptor-positive (ER+), HER2-negative (HER2) metastatic breast cancer.
For detecting and counting CTCs, Menarini Silicon Biosystems’ CELLSEARCH CTC System, a clinically validated blood test approved by the Food and Drug Administration (FDA) was used.
Go deeper with GlobalData
The test helps physicians to manage patients with metastatic breast, prostate, and colorectal cancers when used along with other clinical methods of monitoring.
The randomised trial was conducted on 778 women with Stage 4 ER+, HER2- breast cancer and the outcomes of treatment decisions were compared based on physician assessment versus CTC count.
In the trial, patients in the clinically driven treatment group received treatment selected by a physician based on clinical factors.
In the CTC-driven treatment group, patients with five or more CTCs in 7.5ml of blood received chemotherapy and those with less than five CTCs in 7.5ml received hormone therapy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCELLSEARCH system was used to capture and isolate tumour cells, circulating in the blood in all patients.
The results supported the reliability and clinical utility of using the CTC count to guide front line therapy choice.
The CTC count for most patients in the clinically driven group correlated with the physician’s treatment choice.
In the CTC-driven group, progressing treatment to frontline chemotherapy for patients with high CTC count significantly improved progression-free survival (PFS).
Moreover, for patients with low CTC count, de-escalation to hormone therapy did not have a detrimental impact on PFS or overall survival (OS).
Menarini Silicon Biosystems president and CEO Fabio Piazzalunga said: “The results of the STIC CTC study provide evidence that the CTC count can support physicians when making effective treatment decisions.”
